Clinical Trials Logo

Neoplasm, Residual clinical trials

View clinical trials related to Neoplasm, Residual.

Filter by:

NCT ID: NCT03770299 Not yet recruiting - Clinical trials for Non-Small Cell Lung Cancer

An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease

CheckMate 9TN
Start date: March 15, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if nivolumab added to the standard of care therapy (SOC) given after surgery is more effective than SOC alone in prolonging disease free survival in NSCLC participants with minimal residual disease detected after surgery.

NCT ID: NCT03745352 Not yet recruiting - Clinical trials for Refractory Acute Myeloid Leukemia

Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Start date: May 31, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pevonedistat works with azacitidine compared to azacitidine alone in treating patients with acute myeloid leukemia that has come back or does not respond to treatment. Pevonedistat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if pevonedistat with azacitidine or azacitidine alone may work better in treating patients with acute myeloid leukemia.

NCT ID: NCT03737955 Recruiting - Clinical trials for Acute Myeloid Leukemia

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Participants With Acute Myeloid Leukemia

Start date: November 30, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well fractionated gemtuzumab ozogamicin works in treating measurable residual disease in participants with acute myeloid leukemia. Antibody-drug conjugates, such as gemtuzumab ozogamicin, may block cancer growth in different ways by targeting certain cells.

NCT ID: NCT03703427 Not yet recruiting - Clinical trials for Pathologic Residual Cancer Cells

Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Start date: November 2018
Phase: Phase 2
Study type: Interventional

This study is designed to investigate the efficacy and safety of capecitabine versus vinorelbine as a postoperative adjuvant chemotherapy, for high risk breast cancer patients who have pathologic residual cancer cells after the preoperative chemotherapy.

NCT ID: NCT03699384 Recruiting - Clinical trials for Acute Myeloid Leukemia (AML)

Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

Start date: October 3, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I / II study. The purposes of this study are to: 1) find out what effects, good and/or bad, the combination of the experimental drug avelumab and the drug azacitidine has on people with AML and MRD, and 2) test if the two drugs, avelumab and azacitidine, are effective in getting rid of AML MRD when the drugs are given together in combination.

NCT ID: NCT03697655 Recruiting - Multiple Myeloma Clinical Trials

Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma

PREDATOR
Start date: December 10, 2018
Phase: Phase 2
Study type: Interventional

PREDATOR is a study investigating a role of preemptive daratumumab therapy for preclinical relapse or progression of multiple myeloma (MM).

NCT ID: NCT03686215 Not yet recruiting - Breast Cancer Clinical Trials

Pivotal Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients

Start date: December 2018
Phase: Phase 3
Study type: Interventional

This is a multi-center, single-arm pivotal study to demonstrate the safety and efficacy of the LUM Imaging System (LUM015 imaging agent in conjunction with the LUM Imaging Device and decision software), in identifying residual cancer in the lumpectomy bed of female breast cancer patients undergoing breast in order to assist surgeons in reducing the rates of positive margins. In this study, patients will be injected with LUM015 prior to surgery. The study physician should perform their standard of care lumpectomy, which may include the removal of shaves. Therapeutic (Lumicell guided) shaves will be removed based on the recommendation of the LUM Imaging System after the standard of care lumpectomy. Patients will be followed until their first standard of care post-operative follow-up visit.

NCT ID: NCT03684863 Not yet recruiting - Clinical trials for HER2-positive Breast Cancer

Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Start date: October 2018
Phase: Phase 2
Study type: Interventional

This study is designed to investigate the efficacy and safety of capecitabine, as a postoperative adjuvant chemotherapy, for HER-2 positive breast cancer patients who have pathologic residual cancer cells after the preoperative chemotherapy.

NCT ID: NCT03665480 Recruiting - Clinical trials for Acute Myeloid Leukemia

The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML

Start date: September 4, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Granulocyte-colony stimulating factor (G-CSF) is konwn to have no significant effect on leukemia stem cells and has been widely used in the patients with agranulocytosis after chemotherapy. Minimal residual disease (MRD), an index for early treatment response, plays an important role in prognostic prediction. Numbers of data have shown MRD at day 14 after induction therapy significantly predicts prognosis. However, the retrospetive data from the investigators showed that patients with G-CSF treatment after induction had higher MRD at day 14 but not significantly different at day 28, suggesting that G-CSF might work on the differenciation of hemapoetic stem cells and increase MRD levels at day 14. In this multicenter prospective randomized controlled study, the effect of G-CSF on MRD after induction therapy in newly diagnosed acute myeloid leukemia (AML) is evaluated.

NCT ID: NCT03662087 Recruiting - Clinical trials for Minimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation

HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT

Start date: October 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Allogeneic hematopoietic cell transplantation (Allo-HSCT) is an effective therapy for acute leukemia, but relapse is the most common problem affecting long-term survivors of allo-HSCT. Therapy options for relapse include stopping immune suppression, re-induction of chemotherapy, donor lymphocyte infusion (DLI) or combination therapy. In this prospective randomized controlled study, the safety and efficacy of hypomethylating agents (HMA) + DLI and DLI preemptive therapy based on minimal residual disease in acute leukemia undergoing allo-HSCT are evaluated.